GC Pharma (006280) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH81898D
- Pages: 43
- November 2018
- Total Views:1281
- Region : Asia
- GlobalData
- Equity Research Report
Details
Summary
GC Pharma(GC Pharma) formerly known as Green Cross Corp, a subsidiary of Green Cross Holdings Corp provides plasma protein therapeutics and vaccines. The company develops, manufactures and markets a wide product portfolio comprising plasma derivatives including albumin, immunoglobulin, and antithrombin; vaccines for infectious diseases; prescription drugs for treating cardiovascular, respiratory, central nervous system (CNS), gastrointestinal and immunology diseases, musculoskeletal disorders, genetic disorders, metabolic disorders and hematological disorders; and Over-the-counter (OTC) drugs including anti-inflammatory drugs, anti-allergic products and others. The company focuses its research and development activities at developing pharmaceuticals for difficult to treat diseases, including cancer. GC Pharma is headquartered Yongin-si, Gyeonggi-do, South Korea.
GC Pharma (006280)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
GC Pharma, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GC Pharma, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
GC Pharma, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GC Pharma, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
GC Pharma, Medical Devices Deals, 2012 to YTD 2018 10
GC Pharma, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
GC Pharma, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Argos Therapeutics Raises USD 60 Million In Series E Financing 13
Partnerships 16
Yuhan to Enter into Agreement with GC Pharma 16
Feldan Therapeutics and Green Cross LabCell Enter into Research Partnership 17
AroCell Enters into Co-Development Agreement with Green Cross Cell 18
Green Cross Cell Forms Joint Venture with Harbin Hou pu Tong tang Biotech 19
Green Cross Cell and ToolGen to Enter into Partnership 20
OGD2 Pharma Enters into Agreement with Green Cross LabCell 21
Oxford BioMedica Enters into Agreement with Green Cross 22
Green Cross Enters into Commercialization Agreement with Nanolek 23
Aquavit Pharma Announces Co-Development Agreement With Green Cross For IBX-001 24
Licensing Agreements 25
Lee's Pharma Enters into Licensing Agreement with GC Pharma 25
Green Cross Enters into Licensing Agreement with Argos Therapeutics 26
Equity Offering 28
Green Cross LabCell Prices IPO of Shares for USD32 Million 28
Innocell Completes Private Placement Of Shares For USD 13 Million 29
Debt Offering 30
Green Cross Cell Raises USD55.3 Million in Private Placement of Convertible Bonds 30
Acquisition 31
Green Cross Acquires Additional 7.07% Stake In Ildong Pharma From WhanIn Pharma 31
GC Pharma-Key Competitors 32
GC Pharma-Key Employees 33
GC Pharma-Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 36
Strategy And Business Planning 36
May 20, 2018: GC Pharma to Establish Curevo-a Seattle-based New Company Dedicated to Development of New Vaccines 36
Apr 29, 2017: Green Cross to Build Cell Therapy Manufacturing Facility in China 37
Financial Announcements 38
Oct 30, 2018: GC Pharma reports Q3 2018 results 38
Jul 31, 2018: GC Pharma Reports Q2 2018 Results 39
Apr 27, 2018: GC Pharma Announces Q1 2018 Results 40
Feb 05, 2018: GC Pharma Reports Full Year 2017 Results 41
Product News 42
01/18/2018: GC Pharma Confirms Phase 2/3 Clinical Trial of New Protein Therapy for Hepatitis B 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43
List Of Figure
List of Figures
GC Pharma, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
GC Pharma, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
GC Pharma, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
GC Pharma, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
GC Pharma, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GC Pharma, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
GC Pharma, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GC Pharma, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
GC Pharma, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
GC Pharma, Pharmaceuticals & Healthcare, Key Facts, 2017 2
GC Pharma, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GC Pharma, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
GC Pharma, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GC Pharma, Deals By Therapy Area, 2012 to YTD 2018 9
GC Pharma, Medical Devices Deals, 2012 to YTD 2018 10
GC Pharma, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Argos Therapeutics Raises USD 60 Million In Series E Financing 13
Yuhan to Enter into Agreement with GC Pharma 16
Feldan Therapeutics and Green Cross LabCell Enter into Research Partnership 17
AroCell Enters into Co-Development Agreement with Green Cross Cell 18
Green Cross Cell Forms Joint Venture with Harbin Hou pu Tong tang Biotech 19
Green Cross Cell and ToolGen to Enter into Partnership 20
OGD2 Pharma Enters into Agreement with Green Cross LabCell 21
Oxford BioMedica Enters into Agreement with Green Cross 22
Green Cross Enters into Commercialization Agreement with Nanolek 23
Aquavit Pharma Announces Co-Development Agreement With Green Cross For IBX-001 24
Lee's Pharma Enters into Licensing Agreement with GC Pharma 25
Green Cross Enters into Licensing Agreement with Argos Therapeutics 26
Green Cross LabCell Prices IPO of Shares for USD32 Million 28
Innocell Completes Private Placement Of Shares For USD 13 Million 29
Green Cross Cell Raises USD55.3 Million in Private Placement of Convertible Bonds 30
Green Cross Acquires Additional 7.07% Stake In Ildong Pharma From WhanIn Pharma 31
GC Pharma, Key Competitors 32
GC Pharma, Key Employees 33
GC Pharma, Other Locations 34
GC Pharma, Subsidiaries 34
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
GC Pharma, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
GC Pharma(GC Pharma) formerly known as Green Cross Corp, a subsidiary of Green Cross Holdings Corp provides plasma protein therapeutics and vaccines. The company develops, manufactures and markets a wide product portfolio comprising plasma derivatives including albumin, immunoglobulin, and antithrombin; vaccines for infectious diseases; prescription drugs for treating cardiovascular, respiratory, central nervous system (CNS), gastrointestinal and immunology diseases, musculoskeletal disorders, genetic disorders, metabolic disorders and hematological disorders; and Over-the-counter (OTC) drugs including anti-inflammatory drugs, anti-allergic products and others. The company focuses its research and development activities at developing pharmaceuticals for difficult to treat diseases, including cancer. GC Pharma is headquartered Yongin-si, Gyeonggi-do, South Korea.
GC Pharma (006280)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
GC Pharma, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GC Pharma, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
GC Pharma, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GC Pharma, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
GC Pharma, Medical Devices Deals, 2012 to YTD 2018 10
GC Pharma, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
GC Pharma, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Argos Therapeutics Raises USD 60 Million In Series E Financing 13
Partnerships 16
Yuhan to Enter into Agreement with GC Pharma 16
Feldan Therapeutics and Green Cross LabCell Enter into Research Partnership 17
AroCell Enters into Co-Development Agreement with Green Cross Cell 18
Green Cross Cell Forms Joint Venture with Harbin Hou pu Tong tang Biotech 19
Green Cross Cell and ToolGen to Enter into Partnership 20
OGD2 Pharma Enters into Agreement with Green Cross LabCell 21
Oxford BioMedica Enters into Agreement with Green Cross 22
Green Cross Enters into Commercialization Agreement with Nanolek 23
Aquavit Pharma Announces Co-Development Agreement With Green Cross For IBX-001 24
Licensing Agreements 25
Lee's Pharma Enters into Licensing Agreement with GC Pharma 25
Green Cross Enters into Licensing Agreement with Argos Therapeutics 26
Equity Offering 28
Green Cross LabCell Prices IPO of Shares for USD32 Million 28
Innocell Completes Private Placement Of Shares For USD 13 Million 29
Debt Offering 30
Green Cross Cell Raises USD55.3 Million in Private Placement of Convertible Bonds 30
Acquisition 31
Green Cross Acquires Additional 7.07% Stake In Ildong Pharma From WhanIn Pharma 31
GC Pharma-Key Competitors 32
GC Pharma-Key Employees 33
GC Pharma-Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 36
Strategy And Business Planning 36
May 20, 2018: GC Pharma to Establish Curevo-a Seattle-based New Company Dedicated to Development of New Vaccines 36
Apr 29, 2017: Green Cross to Build Cell Therapy Manufacturing Facility in China 37
Financial Announcements 38
Oct 30, 2018: GC Pharma reports Q3 2018 results 38
Jul 31, 2018: GC Pharma Reports Q2 2018 Results 39
Apr 27, 2018: GC Pharma Announces Q1 2018 Results 40
Feb 05, 2018: GC Pharma Reports Full Year 2017 Results 41
Product News 42
01/18/2018: GC Pharma Confirms Phase 2/3 Clinical Trial of New Protein Therapy for Hepatitis B 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43
List Of Figure
List of Figures
GC Pharma, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
GC Pharma, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
GC Pharma, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
GC Pharma, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
GC Pharma, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GC Pharma, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
GC Pharma, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GC Pharma, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
GC Pharma, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
GC Pharma, Pharmaceuticals & Healthcare, Key Facts, 2017 2
GC Pharma, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GC Pharma, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
GC Pharma, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GC Pharma, Deals By Therapy Area, 2012 to YTD 2018 9
GC Pharma, Medical Devices Deals, 2012 to YTD 2018 10
GC Pharma, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Argos Therapeutics Raises USD 60 Million In Series E Financing 13
Yuhan to Enter into Agreement with GC Pharma 16
Feldan Therapeutics and Green Cross LabCell Enter into Research Partnership 17
AroCell Enters into Co-Development Agreement with Green Cross Cell 18
Green Cross Cell Forms Joint Venture with Harbin Hou pu Tong tang Biotech 19
Green Cross Cell and ToolGen to Enter into Partnership 20
OGD2 Pharma Enters into Agreement with Green Cross LabCell 21
Oxford BioMedica Enters into Agreement with Green Cross 22
Green Cross Enters into Commercialization Agreement with Nanolek 23
Aquavit Pharma Announces Co-Development Agreement With Green Cross For IBX-001 24
Lee's Pharma Enters into Licensing Agreement with GC Pharma 25
Green Cross Enters into Licensing Agreement with Argos Therapeutics 26
Green Cross LabCell Prices IPO of Shares for USD32 Million 28
Innocell Completes Private Placement Of Shares For USD 13 Million 29
Green Cross Cell Raises USD55.3 Million in Private Placement of Convertible Bonds 30
Green Cross Acquires Additional 7.07% Stake In Ildong Pharma From WhanIn Pharma 31
GC Pharma, Key Competitors 32
GC Pharma, Key Employees 33
GC Pharma, Other Locations 34
GC Pharma, Subsidiaries 34
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
GC Pharma, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
: +62 8115065463 
Related Reports
Page 157 | 
June 2021
Page 130 | December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020